JP2019529385A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529385A5
JP2019529385A5 JP2019512292A JP2019512292A JP2019529385A5 JP 2019529385 A5 JP2019529385 A5 JP 2019529385A5 JP 2019512292 A JP2019512292 A JP 2019512292A JP 2019512292 A JP2019512292 A JP 2019512292A JP 2019529385 A5 JP2019529385 A5 JP 2019529385A5
Authority
JP
Japan
Prior art keywords
use according
mammal
cells
cns
therapeutic protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019512292A
Other languages
English (en)
Japanese (ja)
Other versions
JP7610923B2 (ja
JP2019529385A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/049959 external-priority patent/WO2018045347A1/en
Publication of JP2019529385A publication Critical patent/JP2019529385A/ja
Publication of JP2019529385A5 publication Critical patent/JP2019529385A5/ja
Priority to JP2022002163A priority Critical patent/JP2022050574A/ja
Application granted granted Critical
Publication of JP7610923B2 publication Critical patent/JP7610923B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019512292A 2016-09-02 2017-09-01 Cns障害を治療するための方法及びベクター Active JP7610923B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022002163A JP2022050574A (ja) 2016-09-02 2022-01-11 Cns障害を治療するための方法及びベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383274P 2016-09-02 2016-09-02
US62/383,274 2016-09-02
PCT/US2017/049959 WO2018045347A1 (en) 2016-09-02 2017-09-01 Methods and vectors for treating cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022002163A Division JP2022050574A (ja) 2016-09-02 2022-01-11 Cns障害を治療するための方法及びベクター

Publications (3)

Publication Number Publication Date
JP2019529385A JP2019529385A (ja) 2019-10-17
JP2019529385A5 true JP2019529385A5 (enExample) 2020-09-17
JP7610923B2 JP7610923B2 (ja) 2025-01-09

Family

ID=61309371

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019512292A Active JP7610923B2 (ja) 2016-09-02 2017-09-01 Cns障害を治療するための方法及びベクター
JP2022002163A Pending JP2022050574A (ja) 2016-09-02 2022-01-11 Cns障害を治療するための方法及びベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022002163A Pending JP2022050574A (ja) 2016-09-02 2022-01-11 Cns障害を治療するための方法及びベクター

Country Status (9)

Country Link
US (1) US20190192693A1 (enExample)
EP (1) EP3506930A4 (enExample)
JP (2) JP7610923B2 (enExample)
CN (1) CN110121356A (enExample)
AU (2) AU2017318717B2 (enExample)
BR (1) BR112019004353A2 (enExample)
CA (1) CA3035628A1 (enExample)
MX (1) MX2019002518A (enExample)
WO (1) WO2018045347A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
US20200164008A1 (en) * 2017-07-17 2020-05-28 Spark Therapeutics, Inc. Apheresis methods and uses
BR112020025268A2 (pt) * 2018-06-28 2021-03-09 The University Of North Carolina At Chapel Hill Cassetes de expressão e genes cln5 otimizados e seu uso
CN113966399A (zh) 2018-09-26 2022-01-21 加州理工学院 用于靶向基因疗法的腺相关病毒组合物
CA3114175A1 (en) 2018-10-01 2020-04-09 The Trustees Of The University Of Pennsylvania Beta-galactosidase based aav for treating gm1 gangliosidosis
BR112021009370A2 (pt) * 2018-11-14 2021-08-17 Regenxbio Inc. método de tratamento da doença de batten cln2, composição farmacêutica e kit
JP7616995B2 (ja) * 2018-11-28 2025-01-17 プリベイル セラピューティクス,インコーポレーテッド 神経変性疾患のための遺伝子治療
BR112021015817A2 (pt) 2019-02-22 2021-10-13 The Trustees Of The University Of Pennsylvania Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn
WO2021061909A1 (en) * 2019-09-24 2021-04-01 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Method of targeting neuronal apoe to treat a neurocognitive disorder
JP2023500793A (ja) * 2019-10-16 2023-01-11 コーネル・ユニバーシティー アルツハイマー病に対する遺伝子治療方法
EP4065600A1 (en) 2019-11-25 2022-10-05 Cornell University Apoe gene therapy
IL301549A (en) * 2020-10-01 2023-05-01 Sangamo Therapeutics Inc Methods of detecting anti-aav antibodies
CN112852881B (zh) * 2021-02-09 2023-08-15 南京贝思奥生物科技有限公司 利用细胞穿膜肽增强腺相关病毒在中枢神经系统转导效率的方法
TW202426479A (zh) * 2022-10-10 2024-07-01 美商星火治療公司 Apoe基因療法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135339B2 (en) * 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
WO2012057363A1 (ja) 2010-10-27 2012-05-03 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
CN104540952A (zh) * 2012-05-18 2015-04-22 衣阿华大学研究基金会 用于治疗淀粉状蛋白沉积的方法和组合物
EP3024497B1 (en) * 2013-07-26 2021-01-13 University of Iowa Research Foundation Methods and compositions for treating brain diseases
IL245703B (en) * 2013-11-20 2022-07-01 Univ Iowa Res Found Methods and compositions for treating amyloid deposits
AU2016219789B2 (en) * 2015-02-20 2021-03-25 Fondazione Telethon Methods and compositions for treating genetic eye diseases

Similar Documents

Publication Publication Date Title
JP2019529385A5 (enExample)
JP2022508182A5 (enExample)
ES2897508T3 (es) Variantes de virus adenoasociados y métodos de uso de las mismas
JP2020527333A5 (enExample)
ES2903127T3 (es) Terapia génica para trastornos neurodegenerativos
JP2022549140A5 (enExample)
JP2016503405A5 (enExample)
JP2021511803A5 (enExample)
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
HRP20192141T1 (hr) Genska terapija za retinitis pigmentosa
JP2017509632A5 (enExample)
JP2022551744A5 (enExample)
RU2017125234A (ru) Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
JP2020519629A5 (enExample)
JP2017529395A5 (enExample)
JP7616668B2 (ja) Ube3a遺伝子および発現カセットならびにそれらの使用
CA3158518A1 (en) Triple function adeno-associated virus (aav)vectors for the treatment of c9orf72 associated diseases
JP2020509786A5 (enExample)
IL292264B1 (en) Aav transfer cassette
JP2021520811A5 (enExample)
JP2023520763A5 (enExample)
CN114144518A (zh) 用于基因疗法的双亮氨酸拉链激酶抑制剂
JP2023515795A5 (enExample)
JP2024515902A5 (enExample)
HRP20220199T1 (hr) Postupak genetskog liječenja korištenjem virusa aav-xbp1s/gfp i njegova uporaba u prevenciji i liječenju amiotrofične lateralne skleroze